| __timestamp | Insmed Incorporated | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 31073000 | 14993000000 |
| Thursday, January 1, 2015 | 43216000 | 14247000000 |
| Friday, January 1, 2016 | 50679000 | 14192000000 |
| Sunday, January 1, 2017 | 79171000 | 14997000000 |
| Monday, January 1, 2018 | 168218000 | 16471000000 |
| Tuesday, January 1, 2019 | 210796000 | 14369000000 |
| Wednesday, January 1, 2020 | 203613000 | 14197000000 |
| Friday, January 1, 2021 | 234273000 | 14886000000 |
| Saturday, January 1, 2022 | 265784000 | 14253000000 |
| Sunday, January 1, 2023 | 344501000 | 12489000000 |
| Monday, January 1, 2024 | 12566000000 |
Unlocking the unknown
In the world of pharmaceuticals, understanding the financial health of companies is crucial. Over the past decade, Novartis AG and Insmed Incorporated have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Novartis, a global leader, has seen a steady decline in its SG&A expenses, dropping from approximately $15 billion in 2014 to $12.5 billion in 2023. This represents a 17% reduction, reflecting strategic cost management. In contrast, Insmed, a smaller biotech firm, has experienced a dramatic increase in its SG&A expenses, skyrocketing by over 1,000% from $31 million in 2014 to $345 million in 2023. This surge highlights Insmed's aggressive expansion and investment in growth. These trends offer a fascinating glimpse into the strategic priorities of these companies, with Novartis focusing on efficiency and Insmed on growth.
SG&A Efficiency Analysis: Comparing Novartis AG and Regeneron Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Novartis AG and Neurocrine Biosciences, Inc.
Novartis AG or Teva Pharmaceutical Industries Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Novartis AG and Sarepta Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Novartis AG and Ultragenyx Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Novartis AG or Iovance Biotherapeutics, Inc.
Novartis AG or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Novartis AG and Viridian Therapeutics, Inc.
Insmed Incorporated vs Halozyme Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Insmed Incorporated and Pharming Group N.V.
Insmed Incorporated and Opthea Limited: SG&A Spending Patterns Compared
Insmed Incorporated and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared